NCT00686790View on ClinicalTrials.gov

Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Hepatitis D, ChronicHepatitis B, Chronic
Interventions
BIOLOGICAL

Peginterferon alfa-2b (PegIntron, SCH 54031)

Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00686790 - Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) | Biotech Hunter | Biotech Hunter